Wave Life Sciences, Inc. reported that its stockholders approved an amendment to the company’s Amended and Restated 2021 Equity Incentive Plan on November 12, 2026. The amendment authorizes an increase of 11,000,000 shares of common stock for issuance under the plan.

The filing details the voting results from the company’s 2026 Annual Meeting of Stockholders. A quorum of 166,197,073 shares, representing 84% of the eligible shares, was present at the meeting. Stockholders voted on several proposals, including the ratification of the independent registered public accounting firm KPMG LLP for the year ending December 31, 2026.

Regarding the amendment to the equity plan, 119,800,336 shares were voted for, while 22,936,097 were voted against. Additionally, stockholders approved on a non-binding, advisory basis the compensation of the company’s named executive officers, with 133,800,043 shares voting in favor.

The company also reported the re-election of nine directors to the Board of Directors to serve until the 2027 Annual Meeting. The directors elected were Paul B. Bolno, Mark H.N. Corrigan, Christian Henry, Peter Kolchinsky, Adrian Rawcliffe, Ken Takanashi, Aik Na Tan, Gregory L. Verdine, and Heidi L. Wagner.